Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Insights and Trends

• According to DelveInsight’s analysis, the total incidence of promising indications for CAR-T in NHL was ~ 159,000 in the 7MM (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.

• CAR-T therapy in NHL is primarily used in a small subset of relapsed/refractory patients, particularly in aggressive subtypes such as DLBCL and MCL. Its utilization is driven by disease severity, patient eligibility, and access to specialized treatment centers.

• Across the 7MM, CAR T-cell therapy demonstrates promising potential in multiple NHL indications, including Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL) (with the highest number of incident cases around 78,000), Follicular Lymphoma (FL), Primary Mediastinal Large B-Cell Lymphoma (PMBCL), Marginal Zone Lymphoma (MZL), and Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).

• In the United States, CAR T-cell Therapy shows promising potential across NHL indications, with approximately 68,000 cases in 2025.

Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Epidemiology Forecast in 7MM

• 2025 Incident Cases of CAR-T in NHL: ~ 159,000

• 2036 Projected Incident Cases of CAR-T in NHL: XXXX

• CAR-T in NHL  Growth Rate (2026–2036): 1.3% CAGR

DelveInsight's ‘Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's lymphoma (NHL) Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the CAR-T in NHL, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France), and the United Kingdom, and Japan.

Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL)  Understanding 

 CAR-T in NHL Overview

CAR T-cell therapy is a personalized immunotherapy in which a patient’s T cells are modified to target cancer cells, most often CD19-positive B-cell NHL. After reinfusion, these engineered cells identify and destroy malignant cells. It is especially used for relapsed or refractory aggressive lymphomas such as DLBCL. While it has improved outcomes for patients with few other options, careful patient selection is important because the treatment can cause significant toxicities.

CAR-T in NHL Diagnosis

In general, the diagnosis of NHL relies on biopsy as the gold standard to confirm the disease and determine its subtype. This is supported by physical examination, imaging tests such as CT, MRI, and PET-CT to assess disease spread, and bone marrow evaluation. Additionally, biomarker and molecular testing (including NGS, flow cytometry, and immunohistochemistry) help identify specific tumor characteristics and guide advanced treatments like CAR T-cell Therapy.

Further details are provided in the report.

Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Epidemiology

Key Findings from CAR-T in NHL Epidemiological Analysis and Forecast 

• According to DelveInsight estimates, the total incident cases of selected CAR-T indications in NHL across the 7MM were approximately 159,000 in 2025 and are expected to rise throughout the forecast period from 2026 to 2036.

• The least incident cases in the 7MM among all the selected indications were for PMBCL, accounting for ~ 5,700 cases in 2025.

• In the United States, the target patient pool for DLBCL is estimated to be around 32,800 patients in 2025.

Scope of the Report

The report covers a segment of an executive summary, a descriptive overview of CAR-T in NHL, explaining its causes, signs and symptoms, and pathogenesis.

• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

CAR-T in the NHL patient population forecast

Report Key Strengths

• Epidemiology‑based (epi‑based) bottom‑up forecasting

• 11-year forecast 

• Patient burden trends (by geography)

FAQs

• What are the disease risks, burdens, and unmet needs of CAR-T in NHL? What will be the growth opportunities across the 7MM concerning the patient population with CAR-T in NHL?

• What is the historical and forecasted CAR-T in the NHL patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.

• To understand key opinion leaders’ perspectives on the diagnostic challenges to overcome barriers in the future.

• Detailed insights into various factors hampering disease diagnosis and other existing diagnostic challenges.